Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease

We studied whether combinations of botanical extracts enriched in either Δ9‐tetrahydrocannabinol (Δ9‐THC) or cannabidiol (CBD), which are the main constituents of the cannabis‐based medicine Sativex, provide neuroprotection in rat models of Huntington's disease (HD). We used rats intoxicated with 3‐nitropropionate (3NP) that were given combinations of Δ9‐THC‐ and CBD‐enriched botanical extracts. The issue was also studied in malonate‐lesioned rats. The administration of Δ9‐THC‐ and CBD‐enriched botanical extracts combined in a ratio of 1:1 as in Sativex attenuated 3NP‐induced GABA deficiency, loss of Nissl‐stained neurons, down‐regulation of CB1 receptor and IGF‐1 expression, and up‐regulation of calpain expression, whereas it completely reversed the reduction in superoxide dismutase‐1 expression. Similar responses were generally found with other combinations of Δ9‐THC‐ and CBD‐enriched botanical extracts, suggesting that these effects are probably related to the antioxidant and CB1 and CB2 receptor‐independent properties of both phytocannabinoids. In fact, selective antagonists for both receptor types, i.e., SR141716 and AM630, respectively, were unable to prevent the positive effects on calpain expression caused in 3NP‐intoxicated rats by the 1:1 combination of Δ9‐THC and CBD. Finally, this combination also reversed the up‐regulation of proinflammatory markers such as inducible nitric oxide synthase observed in malonate‐lesioned rats. In conclusion, this study provides preclinical evidence in support of a beneficial effect of the cannabis‐based medicine Sativex as a neuroprotective agent capable of delaying disease progression in HD, a disorder that is currently poorly managed in the clinic, prompting an urgent need for clinical trials with agents showing positive results in preclinical studies. © 2011 Wiley‐Liss, Inc.

[1]  J. Lucas,et al.  Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. , 2011, Brain : a journal of neurology.

[2]  DelindaA . Johnson,et al.  Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription , 2010, Experimental Neurology.

[3]  Elena Cattaneo,et al.  Molecular mechanisms and potential therapeutical targets in Huntington's disease. , 2010, Physiological reviews.

[4]  Anil Kumar,et al.  Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats. , 2010, European journal of pharmacology.

[5]  B. Davidson,et al.  Huntington's disease: progress toward effective disease-modifying treatments and a cure. , 2010, Human molecular genetics.

[6]  D. Ehrnhoefer,et al.  Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. , 2010, Human molecular genetics.

[7]  J. Fernández-Ruiz,et al.  The endocannabinoid system as a target for the treatment of neuronal damage , 2010, Expert opinion on therapeutic targets.

[8]  N. Déglon,et al.  Mitochondria in Huntington's disease. , 2010, Biochimica et biophysica acta.

[9]  I. Mitchell,et al.  A pilot study using nabilone for symptomatic treatment in Huntington's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.

[10]  Í. Azcoitia,et al.  Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. , 2009, Brain : a journal of neurology.

[11]  V. García-Martínez,et al.  Kaempferol protects against rat striatal degeneration induced by 3‐nitropropionic acid , 2009, Journal of neurochemistry.

[12]  E. Brouillet,et al.  Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease , 2009, Glia.

[13]  M. Beal,et al.  Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases , 2009, Journal of neurochemistry.

[14]  R. Pertwee,et al.  Emerging strategies for exploiting cannabinoid receptor agonists as medicines , 2009, British journal of pharmacology.

[15]  J. Martínez-Orgado,et al.  Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets , 2008, Pediatric Research.

[16]  J. Fernández-Ruiz,et al.  The endocannabinoid system in Huntington's disease. , 2008, Current pharmaceutical design.

[17]  C. Ríos,et al.  Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NOx Content in the CSF. A Different Marker Profile in Four Neurodegenerative Diseases , 2008, Neurochemical Research.

[18]  R. Mechoulam,et al.  Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors , 2007, The European journal of neuroscience.

[19]  Alexandra Durr,et al.  Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression , 2007, PloS one.

[20]  S. Wright Cannabinoid-Based Medicines for Neurological Disorders—Clinical Evidence , 2007, Molecular Neurobiology.

[21]  K. Nicolay,et al.  Acute neuronal injury, excitotoxicity, and the endocannabinoid system , 2002, Molecular Neurobiology.

[22]  G. Velasco,et al.  Cannabinoid CB2 receptor: a new target for controlling neural cell survival? , 2007, Trends in pharmacological sciences.

[23]  M. Scattoni,et al.  The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum , 2006, Neuropharmacology.

[24]  J. Pedraza-Chaverri,et al.  S-Allylcysteine prevents the rat from 3-nitropropionic acid-induced hyperactivity, early markers of oxidative stress and mitochondrial dysfunction , 2006, Neuroscience Research.

[25]  H. Duggal Nabilone Could Treat Chorea and Irritability in Huntington ’ s Disease , 2006 .

[26]  G. Guy,et al.  A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. , 2006, Medical hypotheses.

[27]  D. Blum,et al.  3‐Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease , 2005, Journal of neurochemistry.

[28]  A. Abdel-Naim,et al.  Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype , 2005, Pharmacology Biochemistry and Behavior.

[29]  Heh-In Im,et al.  Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum , 2005, Brain Research.

[30]  M. Muñoz,et al.  Treatment with Dehydroepiandrosterone Prevents Oxidative Stress Induced by 3-Nitropropionic Acid in Synaptosomes , 2005, Pharmacology.

[31]  R. Mechoulam,et al.  Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease , 2005, Neurobiology of Disease.

[32]  S. Schiffmann,et al.  Minocycline in phenotypic models of Huntington's disease , 2005, Neurobiology of Disease.

[33]  Y. Kan,et al.  Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Ramos,et al.  Cannabinoids in neurodegeneration and neuroprotection , 2005 .

[35]  E. Brouillet,et al.  Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo , 2004, Neuroreport.

[36]  Philippe Hantraye,et al.  In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal Degeneration , 2003, Journal of Biological Chemistry.

[37]  S. Krajewski,et al.  Calpain Is a Major Cell Death Effector in Selective Striatal Degeneration Induced In Vivo by 3-Nitropropionate: Implications for Huntington's Disease , 2003, The Journal of Neuroscience.

[38]  A. Makriyannis,et al.  Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease , 2003, Journal of neurochemistry.

[39]  J. Manzanares,et al.  Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease , 2002, Synapse.

[40]  Beat Lutz,et al.  Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1 , 2002, Journal of neurochemistry.

[41]  R. Rosenthal,et al.  Neuroprotective Antioxidants from Marijuana a , 2000, Annals of the New York Academy of Sciences.

[42]  Françoise Condé,et al.  Replicating Huntington's disease phenotype in experimental animals , 1999, Progress in Neurobiology.

[43]  P. Gluckman,et al.  The IGF-I Amino-Terminal Tripeptide Glycine-Proline-Glutamate (GPE) Is Neuroprotective to Striatum in the Quinolinic Acid Lesion Animal Model of Huntington's Disease , 1999, Experimental Neurology.

[44]  S. Tabrizi,et al.  Biochemical abnormalities and excitotoxicity in Huntington's disease brain , 1999, Annals of neurology.

[45]  J. Axelrod,et al.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M.,et al.  Cannabidiol and (2)D9-tetrahydrocannabinol are neuroprotective antioxidants , 1998 .

[47]  M. Beal,et al.  Neurochemical substrates of rigidity and chorea in Huntington's disease. , 1993, Brain : a journal of neurology.

[48]  S. Snider,et al.  Controlled clinical trial of cannabidiol in Huntington's disease , 1991, Pharmacology Biochemistry and Behavior.

[49]  D. Lust Maps and Guide to Microdissection of the Rat Brain , 1988, Neurology.

[50]  Joseph B. Martin Huntington's disease , 1984, Neurology.

[51]  B. Manyam,et al.  Isoniazid‐induced elevation of CSF GABA levels and effects on chorea in huntington's disease , 1981, Annals of neurology.